Literature DB >> 16132524

Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.

Kajetan L von Eckardstein1, Regina Reszka, Jürgen C W Kiwit.   

Abstract

Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy. Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels. Used as a host for cytotoxic drugs, the gel-like matrix can easily be applied to the walls of a surgical resection cavity. For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study. A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages. Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel. In the latter group, brain edema was markedly reduced and dealt medically. Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132524     DOI: 10.1007/s11060-004-7559-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  18 in total

Review 1.  The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review.

Authors:  L C Marras; W H Geerts; J R Perry
Journal:  Cancer       Date:  2000-08-01       Impact factor: 6.860

2.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Authors:  F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.

Authors:  C A Hurwitz; L C Strauss; J Kepner; C Kretschmar; M B Harris; H Friedman; L Kun; R Kadota
Journal:  J Pediatr Hematol Oncol       Date:  2001 Jun-Jul       Impact factor: 1.289

4.  Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases.

Authors:  Kajetan L von Eckardstein; Stephan Patt; Christine Kratzel; Jürgen C W Kiwit; Regina Reszka
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

5.  A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.

Authors:  Steven A Limentani; Anthony Asher; Michael Heafner; Joseph W Kim; Robert Fraser
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

6.  Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat.

Authors:  A Olivi; M G Ewend; T Utsuki; B Tyler; A J Domb; D J Brat; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

7.  Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures.

Authors:  A I Qureshi; M F Suri; J Khan; M Sharma; K Olson; L R Guterman; L N Hopkins
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

8.  Lipid and water diffusion in bicontinuous cubic phases measured by NMR.

Authors:  P O Eriksson; G Lindblom
Journal:  Biophys J       Date:  1993-01       Impact factor: 4.033

Review 9.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

10.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma.

Authors:  K A Walter; M A Cahan; A Gur; B Tyler; J Hilton; O M Colvin; P C Burger; A Domb; H Brem
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

View more
  5 in total

1.  Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.

Authors:  Feihu Wang; Michael Porter; Alexandros Konstantopoulos; Pengcheng Zhang; Honggang Cui
Journal:  J Control Release       Date:  2017-09-25       Impact factor: 9.776

2.  Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.

Authors:  Silke Glage; Andrew L Lewis; Patricia Mertens; Steffen Baltes; Peter Geigle; Thomas Brinker
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

3.  Radiosensitization of malignant gliomas following intracranial delivery of paclitaxel biodegradable polymer microspheres.

Authors:  Patrik Gabikian; Betty M Tyler; Irma Zhang; Khan W Li; Henry Brem; Kevin A Walter
Journal:  J Neurosurg       Date:  2014-03-07       Impact factor: 5.115

4.  Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.

Authors:  Steffen Baltes; Ina Freund; Andrew L Lewis; Ingo Nolte; Thomas Brinker
Journal:  J Mater Sci Mater Med       Date:  2010-02-17       Impact factor: 3.896

Review 5.  Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review.

Authors:  Roberta Balansin Rigon; Márcia Helena Oyafuso; Andressa Terumi Fujimura; Maíra Lima Gonçalez; Alice Haddad do Prado; Maria Palmira Daflon Gremião; Marlus Chorilli
Journal:  Biomed Res Int       Date:  2015-05-11       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.